QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • NanoViricides Inc. (NNVC) Adds Drug Candidate to Anti-influenza Therapeutics Program, Prepares for FDA Submission 0 comments
    Sep 7, 2011 10:06 AM | about stocks: NNVC

    NanoViricides Inc. yesterday announced it has selected a clinical candidate, now designated NV-INF-1, for FDA submission in its highly successful FluCide™ anti-influenza therapeutics program. Based on NV-INF-1′s demonstrated efficacy as a highly effective anti-influenza drug in animal studies, NanoViricides said it believes the candidate will be rapidly and widely recognized as treatment for severe influenza.

    FDA consultants are assisting the company in developing additional information on NV-INF-1 to prepare for the pre-IND application to the FDA.

    NV-INF-1 is expected to be effective against most strains and types of influenzas, including novel epidemic influenza strains such as the swine flu; seasonal flu such as H1N1, H3N2; highly pathogenic types such as H7N and H9N; and the “bird flu,” or H5N1. The company plans on designating NV-INF-1 for two separate indications: high strength dosage form for hospitalized patients with severe influenza; and a single course therapy for the out-patients with less severe influenza.

    The company noted that the market size for anti-influenza drugs is currently estimated to be approximately $4 billion-$7 billion worldwide. If its FluCide™ drug becomes available, the company anticipates that the market could significantly increase.

    Previous studies showed high efficacy for its optimized FluCide™ drug candidates, prompting the company to focus its efforts on advancing one of the tested optimized FluCide candidates as the clinical drug candidate.

    NanoViricides’ development portfolio includes drugs against several viral diseases, including HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

    For more information visit nanoviricides.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: NNVC
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.